RxDoctor Payments Data

John Giffen, APRN

Psychiatric/Mental Health · Nashville, TNNPI 1184270068

Payments from drug & device makers

$3,583in general payments, 2019–2025

Across 235 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$542
  • Teva Pharmaceuticals USA, Inc.$470
  • Alkermes, Inc.$464
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$417
  • Otsuka America Pharmaceutical, Inc.$108
  • plus $463 from 11 others

What the payments were for

  • Food & beverage$3,53299%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,583 in reported general payments places this provider in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$9,863
Medicare patients
30
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LybalviOlanzapine/Samidorphan Malate20$30,092
VraylarCariprazine Hcl14$20,128
Lurasidone Hcl60$15,124
Aripiprazole90$10,969
TrintellixVortioxetine Hydrobromide15$7,071
Ziprasidone Hcl29$6,872
Chlorpromazine Hcl22$5,267
Paliperidone ErPaliperidone25$2,664
Risperidone94$2,410
Divalproex Sodium55$2,063
Trazodone Hcl273$2,047
Lamotrigine128$1,698
Hydroxyzine Hcl81$1,566
Oxcarbazepine22$1,492
Quetiapine Fumarate98$1,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi$464$30,09220 claims
AbbVieVraylar$1,119$20,12814 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$52$7,07115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →